Standout Papers

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborativ... 2004 2026 2011 2018 1.7k
  1. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group (2008)
    Jean‐Pierre Pignon, Hélène Tribodet et al. Journal of Clinical Oncology
  2. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer (2017)
    Solange Peters, D. Ross Camidge et al. New England Journal of Medicine
  3. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (2004)
    Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology
  4. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 (2004)
    Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology
  5. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial (2017)
    Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology
  6. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. (1999)
    Manel Esteller, Montse Sánchez‐Céspedes et al. PubMed
  7. Non-small-cell lung cancer (2015)
    Cesare Gridelli, Antônio Rossi et al. Nature Reviews Disease Primers
  8. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020)
    Tony Mok, D. Ross Camidge et al. Annals of Oncology
  9. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations (2018)
    Tony Mok, Ying Cheng et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 12 from Science/Nature 173 standout
Sub-graph 1 of 13

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Lung cancer
2021 Standout
69 intermediate papers

Works of Rafael Rosell being referenced

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
2016
and 41 more

Author Peers

Author Last Decade Papers Cites
Rafael Rosell 16187 14871 9816 541 26.1k
D. Ross Camidge 16480 14715 8384 533 23.6k
Lecia V. Sequist 17898 19112 10020 364 30.1k
Federico Cappuzzo 16525 16586 6863 354 24.0k
Benjamin Solomon 13677 12283 6482 407 20.0k
David R. Gandara 18069 16654 7907 641 29.1k
Giorgio V. Scagliotti 19104 16694 8252 475 28.9k
Gregory J. Riely 23302 19166 10730 358 30.7k
Alice T. Shaw 18004 15554 9442 328 24.4k
Suresh S. Ramalingam 14115 15160 8642 584 24.7k
Kenneth J. O’Byrne 10276 12402 8206 586 23.0k

All Works

Loading papers...

Rankless by CCL
2026